A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity,
Role: PI,
Ipsen Pharma SAS,
(04/2025)
Status: Approved
An Open-Label Study to Evaluate the Phannacokinetics, Phannacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barre Syndrome. Protocol: ANX00S-GBS-05,
Role: PI,
Annexon, Inc.,
(04/2026 - 04/2027)
Status: Approved
GORE® CARDIOFORM Septal Occluder and Antiplatelet medical management for reduction of recurrent stroke in patients with Patent Foremen Ovale (PFO): The REDUCE post approval study,
Role: Investigator,
W.L. Gore & Associates, Inc.,
(05/2026 - 05/2027)
Status: Approved
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JXlO in Acute lschemic Stroke with Late Presentations. Protocol: Jx:10002,
Role: PI,
Corxel Pharmaceuticals,
(02/2026 - 02/2027)
Status: Approved
Internal
Early detection of Dementia using Loma Linda Learning and Memory Assessment (LLAMA),
Role: Investigator,
LLU Dept. of Neurology,
(04/2026)
Status: Approved
Non-Profit Organization
A RANDOMIZED CONTROLLED, OPEN-LABEL, RATER-BLINDED PRAGMATIC TRIAL, "TREATMENT OF INFLAMMATORY MYELITIS AND OPTIC NEURITIS WITH EARLY VERSUS RESCUE PLASMA EXCHANGE" (TIMELY-PLEX),
Role: PD/PI,
Mayo Clinic,
(07/2026 - 06/2031)
Status: Awarded